HITRUST® to Address Market Gaps in Reliability and Challenges in the Exchange of Security and Privacy Assessments
6.10.2021 16:00:00 EEST | Business Wire | Press release
HITRUST® announced today a major expansion of its assessment portfolio to raise the quality and efficiency of assurances across the spectrum of information assurance needs. HITRUST also is unveiling a new evolutionary approach to streamline the exchange and consumption of assessment results across the ecosystem of relying parties.
HITRUST CSF Certification is the most reliable information assurance report on the market and made possible by the transparency and consistency in the selection of controls, and in the scoring, and validation of controls by both qualified third-party assessors and the HITRUST Assurance and Quality teams. The assurance process is rigorous by design to ensure a high level of assurance in the results provided. However, there are many situations where a moderate or low level of assurance is warranted. Organizations are seeking a broader range of assessment options that require less effort and time to perform while still providing a commensurate level of reliability for moderate- to lower-risk scenarios.
To meet the market needs for varying levels of assurance with higher reliability, HITRUST is adding two new assessment offerings. Like the HITRUST CSF Validated Assessment, these new offerings will aid in understanding control effectiveness as well as cyber preparedness and resilience. With the two new additions, the HITRUST assessment portfolio will include:
- The Basic Current State (bC) Assessment is a “good hygiene” assessment and offers higher reliability than self-assessments and questionnaires by utilizing the HITRUST Assurance Intelligence Engine™ (AI Engine) to identify errors, omissions, and deceit.
- The Implemented One-Year (i1) Validated Assessment is a “best practices” assessment and recommended for situations that present moderate risk or where a baseline risk assessment is needed. The i1 is designed to provide higher levels of transparency, integrity, and reliability over existing moderate assurance reports, with comparable levels of time, effort, and cost. HITRUST Authorized External Assessors will validate i1 assessments.
- The industry standard HITRUST CSF Validated Assessment is a risk-based and tailorable assessment, which continues to provide the highest level of assurance for situations with greater risk exposure due to data volumes, regulatory compliance, or other risk factors. The HITRUST CSF Validated Assessment will be renamed the Risk-based, Two-Year (r2) Validated Assessment.
Until now, most low to moderate risk assessment mechanisms were either self-attested or validated against unsuitable or inconsistent control selection and limited and subjective assurance programs; which makes it difficult for relying parties to understand the control requirements and depth, breadth, and consistency of the assurance process, limiting the usefulness and reliability of the results.
“Often, organizations utilize mid-level assurance reports such as a SOC 2 report because they take less time and effort while being less costly. Unfortunately, these mid-level assurance reports lack the consistency and reliability of more comprehensive assessments like HITRUST,” said John Houston, Vice President of Information Security and Privacy at UPMC. “The HITRUST i1 Assessment fills a gap in the market for a medium assurance assessment that delivers a higher level of reliability and consistency while having a similar effort and cost to a SOC 2 report. And it can help the organization move towards full HITRUST CSF Certification—which organizations like UPMC view as the gold standard.”
While reliability is crucial for assurance, the accessibility, usability, and consumption of the results are just as important if organizations are to manage supply chain risk given evolving cyber threats. The current method of obtaining and consuming assessment results by the relying party often results in delays, inefficiencies, and misinterpretations as it is based on the exchange of PDF files that are reviewed to determine the scope, scoring, and corrective action plans before key information is often manually entered into a third-party risk management (TPRM) system.
To meet the expanding demand for effective information risk management across the supply chain, the HITRUST Results Distribution System (RDS) will enable assessed entities to deliver their HITRUST Assessment results through a secure, centralized reporting hub to relying parties, eliminating the need for exchanging PDFs and the manual review and entry into third-party systems that subsequently occurs. Recipients will be able to customize dashboards to view the results that interest them most, including scope, aggregate, or specific control scores. In addition, integration with GRC/VRM platforms will be available via API.
“For third-party risk management systems to achieve their full potential in helping organizations manage their vendor risk, assessment results need to be electronically shared and consumed,” said Jeremy Fisher, Vice President of Product at Archer. “HITRUST’s Results Distribution System is a big step in making that possible and will be a strong complement to our focus on vendor interaction through Archer Engage.”
The expansion of the HITRUST Assessment Portfolio and the addition of the RDS further extend HITRUST’s position as an innovator and leader in information risk management, compliance, and assurance. HITRUST continues to drive higher assurances and greater efficiencies into the assurance ecosystem. “HITRUST is building upon our market leadership in providing Rely-Able assurances by introducing moderate and low-level information assurance products,” said Bimal Sheth, Executive Vice President, Standards Development and Assurance Operations, HITRUST. “No other assessment or certification organization is able to meet the expanding global market need for information assessments and electronic results distribution.”
The industry standard r2 assessment (HITRUST CSF Validated Assessment) is currently available while the bC and i1 assessments will be offered to the market later this year. Any i1 or r2 assessment submitted with a reservation is backed by a service-level guarantee to deliver the assessment report within 45 days.
To Learn More:
About HITRUST®
Since it was founded in 2007, HITRUST has championed programs that safeguard sensitive information and manage information risk for organizations across all industries and throughout the third-party supply chain. In collaboration with privacy, information security, and risk management leaders from the public and private sectors, HITRUST develops, maintains, and provides broad access to its widely adopted common risk and compliance management frameworks as well as related assessment and assurance methodologies. For more information, visit www.hitrustalliance.net.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005249/en/
Contact information
Media Contact: Marc Fitzpatrick, e: marc.fitzpatrick@hitrustalliance.net, t: 469.269.1230
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
